• Product NameMLN2238(Ixazomib)
• Brief DescriptionInhibitors
• Purification98.92%
• Biological ActivityMLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.
• Target NameProteasome inhibitor
• CAS No. 1072833-77-2
• Calculated MW 361.03
• Formulation C14H19BCl2N2O4
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:B([C@H](CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O
  Pathways:Proteases/Proteasome; Ubiquitination
  Receptor:20S proteasome; 20S proteasome
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 9 mg/mL (24.92 mM); DMSO: 72 mg/mL (199.42 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Kupperman E, et al. Y Res, 2010, 70(5), 1970-80

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting